VJHemOnc is committed to improving our service to you

IMW 2019 | MRD evaluation: a key component of MM management?

VJHemOnc is committed to improving our service to you

Elena Zamagni, Joaquin Martinez-Lopez and Mohamad Mohty

Mohamad Mohty, MD, PhD, University Pierre & Marie Curie, Paris, France, Elena Zamagni, MD, PhD, University of Bologna, Bologna, Italy, and Joaquin Martinez-Lopez, MD, PhD, Complutense University of Madrid, Madrid, Spain, discuss if measurable residual disease (MRD) could be used as an endpoint for multiple myeloma (MM), which techniques should be used to measure MRD and how to combine it with imaging techniques. The speakers debate whether MRD status should guide drug development and approval, and highlight that it is important to standardize measurement methods and definitions as much as possible, before using MRD routinely. This roundtable was held at the International Myeloma Workshop (IMW) 2019, in Boston, MA.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter